Multiple Sclerosis
Lower brain volumes found in patients with both MS and obstructive sleep apnea
DENVER — In adults with multiple sclerosis, obstructive sleep apnea increases brain atrophy independent of obesity, a common comorbidity, according to a poster at the American Academy of Neurology annual meeting.
Relapse, disease progression uncommon with immune checkpoint inhibitors in MS
DENVER – For older adults with MS and signs of cancer, treatment with immune checkpoint inhibitors was safe and prevented relapse or disease progression, according to interim research.
Preventive pharmacological therapy may help treat urolithiasis, hypercalciuria symptoms
Preventive pharmacological therapy may help to reduce reoccurring symptoms in patients with urolithiasis and hypercalciuria, according to data from a retrospective cohort study.
Spatial mapping of MS-related lesions may be effective as diagnostic, therapeutic tool
WEST PALM BEACH, Fla. — Spatial mapping of lesional tissue is a precise method to identify key functional interactions that may lead to successful therapeutic intervention in multiple sclerosis, according to a presenter at ACTRIMS 2024.
Diversity of MS clinical trials necessary to improve outcomes for underrepresented groups
WEST PALM BEACH, Fla. — Inclusion of underrepresented racial and ethnic groups, along with older patients, patients from rural areas and uninsured patients in multiple sclerosis-targeted clinical trials is likely to improve outcomes, according to a speaker.
‘Rural-urban gap’ for cancer screening exists among women seen at community health centers
English proficiency, income and insurance type could factor into why women cared for at rural community health centers screen for cervical less than those who receive health care services at urban community health centers.
Clemastine fumarate linked to accelerated disability progression in MS
WEST PALM BEACH, Fla. — Treatment with clemastine fumarate was linked to accelerated disease and disability progression due to pyroptosis in a small cohort of individuals with multiple sclerosis, according to a presenter at ACTRIMS 2024.
FDA grants breakthrough designation to vagus nerve stimulation device
The FDA has approved breakthrough device designation for a novel neuroimmune modulation platform for those with relapsing-remitting multiple sclerosis, according to the manufacturer.
Evobrutinib nonsuperior to teriflunomide for relapsing forms of MS
WEST PALM BEACH, Fla. — Treatment with evobrutinib was nonsuperior to teriflunomide in confirmed disability progression at 12 and 24 weeks for those with relapsing forms of multiple sclerosis, according to a presenter at ACTRIMS 2024.
‘Wearing off’ monoclonal antibodies leads to patient dissatisfaction, depression in MS
WEST PALM BEACH, Fla. — The “wearing-off” effect with monoclonal antibodies prescribed for multiple sclerosis led to treatment dissatisfaction and was associated with depression, according to a poster from ACTRIMS 2024.